Similar to sotorasib, adagrasib is a KRAS G12C inhibitor that has demonstrated a great activity on tumor regression in cell lines and patient-derived xenograft models, as well as in vivo, showing tumor regression in 65% of KRAS G12C mutant preclinical models including different tumor histotypes (67). This evidence concerns the gene KRAS and neoplasm.